The industry size of calcium supplement in Korea is estimated to be USD 96 million in 2023. The industry is estimated to surpass USD 279.4 million by 2033, exhibiting 11.3% CAGR.
The industry analysis suggests that demand for personal care products and dietary supplements drives the trend of health related supplementation like calcium supplement.
Size, Analysis and Insights of Calcium Supplement Industry in Korea
Attributes | Details |
---|---|
Korea Calcium Supplement Industry Value for 2023 | USD 96 million |
Projected Industry Value for 2033 | USD 279.4 million |
Value-based CAGR for 2023 to 2033 | 11.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The report on the calcium supplement industry in Korea can be divided into two segments: form and end use, with a notable dominance observed in the soft gel form and men end use categories.
The soft gel segment is expected to hold an industry share of 56.1% in 2023. It dominates the industry owing to its advantages, such as being easier to swallow and being ideal for oil- and fat-soluble formulations. The addition of carrageenan in vegetarian and vegan encapsulation enables people with dietary constraints to have more options in their supplement, vitamin, and mineral selections.
Attributes | Details |
---|---|
Form | Soft Gel |
Industry Share in 2023 | 56.1% |
The men's segment is expected to account for an industry share of 36.4% in 2023 due to the increasing use of supplements by men. The rising health consciousness and gymnasium lifestyle among men are expected to create significant opportunities for calcium supplement sales in Korea.
Attributes | Details |
---|---|
End Use | Men |
Industry Share in 2023 | 36.4% |
Companies like Dong-A Pharmaceutical Co., Ltd., Youngpoong Pharma Corporation, Kyungdong Pharmaceutical Co., Ltd., and Green Cross Pharma Corporation already have a strong foothold in the industry. Manufacturers are creating strong brand identities through effective marketing strategies to boost customer retention. Manufacturing processes are being improved, and the supply chain is being optimized to enhance capacity and meet increased demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Dong-A Pharmaceutical Co., Ltd
Founded in 1945, Dong-A Pharmaceutical Co., Ltd. is one of the leading pharmaceutical companies in South Korea. The company produces a wide range of pharmaceutical products, including calcium supplements. Dong-A Pharmaceutical's calcium supplements are made with high-quality ingredients and have been clinically proven to be effective in increasing bone density and reducing the risk of osteoporosis.
Youngpoong Pharma Corporation
Youngpoong Pharma Corporation is a pharmaceutical company in South Korea. The company was founded in 1973 and produces a wide range of pharmaceutical products, including calcium supplements. Youngpoong Pharma's calcium supplements are made with high-quality ingredients and are clinically proven to be effective in increasing bone density and reducing the risk of osteoporosis.
Attribute | Details |
---|---|
Estimated Industry Size in 2023 | USD 96 million |
Projected Industry Size by 2033 | USD 279.4 million |
Anticipated CAGR between 2023 to 2033 | 11.3% CAGR |
Historical Analysis of Demand for Calcium supplement in Korea | 2018 to 2022 |
Demand Forecast for Calcium supplement in Korea | 2023 to 2033 |
Report Coverage | Industry Size, Industry Trends, Key Insights for Calcium supplement adoption in Korea, Insights on Global Players and Leading Industry Strategy in Korea, Ecosystem Analysis of Local and Regional. |
Key Companies Profiled | Dong-A Pharmaceutical Co., Ltd.; Youngpoong Pharma Corporation; Kyungdong Pharmaceutical Co., Ltd.; Green Cross Pharma Corporation; Samyang Holdings Co., Ltd.; First Pharmaceutical Co., Ltd.; JW Pharmaceutical Co., Ltd.; Chunyang Pharmaceutical Co., Ltd.; Hansong Pharmaceutical Co., Ltd.; Ottogi Corporation; GSK; Pfizer; Bayer; Novartis; Abbott; Eisai; Takeda; Astellas; AstraZeneca; Sanofi |
In 2023, the size of the calcium supplement in Korea is estimated to be USD 96 million.
Increased demand for personal care products and increasing health consciousness are key trends in the calcium supplement industry in Korea.
The calcium supplement industry in Korea is expected to progress at a remarkable CAGR of 11.3% from 2023 to 2033.
By 2033, the industry size of the calcium supplement in Korea is forecasted to reach USD 279.4 million.
Dong-A Pharmaceutical Co., Ltd., Youngpoong Pharma Corporation, Kyungdong Pharmaceutical Co., Ltd., Green Cross Pharma Corporation are some of the prominent players in the calcium supplement in Korea.
1. Executive Summary 2. Market Overview 3. Market Background 4. Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033 5. Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Gummy 5.2. Pill 5.3. Capsule 5.4. Liquid 5.5. Others 6. Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Product 6.1. Calcium Carbonate 6.2. Calcium Gluconate 6.3. Calcium Citrate 6.4. Calcium Lactate 6.5. Calcium Phosphate 6.6. Calcium Orotate 7. Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Applications 7.1. Adult 7.2. Children 8. Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. South Gyeongsang 8.2. North Jeolla 8.3. South Jeolla 8.4. Jeju 8.5. Rest of 9. South Gyeongsang Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 10. North Jeolla Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 11. South Jeolla Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 12. Jeju Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 13. Rest of Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033 14. Market Structure Analysis 15. Competition Analysis 15.1. Omya 15.2. Pipelinepharma 15.3. Pfizer (Caltrate) 15.4. AandZ Pharmaceutical 15.5. Amway (Nutrilite) 15.6. Shanxi Zhendong Pharmaceutical Co., Ltd. 15.7. Nature Made 15.8. By-health Co., Ltd. 15.9. Harbin Pharmaceutical Group 15.10. Bayer AG 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Food and Beverage Insights
View Reports